The July 2013 Issue of The Burrill Report - 06/28/2013

Will Harlem Be the Next Hotspot for Innovation?
Podcast: July 8, 2013 Read More
Cardio3 BioSciences Goes Public
Belgian biotech’s IPO brings to 30 the number of completed life sciences initial public offerings so far in 2013. Read More
California Life Sciences Companies Lead in Venture Financings
Golden State startups account for 38 percent of total raised in first half of 2013. Read More
SEC Investigates Call Options Trading of Onyx Pharmaceuticals Stock
The weekly round-up of failed trials, missed targets, and other business mishaps. Read More
Biogen licenses Myelin Repair Foundation Tech in Fight Against MS
MRF mouse model provides unique characteristics for development of wide range of therapeutics. Read More
Genentech Strikes Immunotherapy Deal with Immunocore
Biotech’s platform generates modified T-cell receptors as drugs that target cancer and viral infection. Read More
FDA Gives Antibacterial Drug Developers New Guidance
To address growing drug resistance, agency seeks new mechanisms of action, ability to neutralize resistance. Read More
Eisai Suspends Sales of Anti-epileptic Drug Fycompa In Germany
Japanese drugmaker says assessment falls short of recognizing its product's value. Read More
Unique Treatment for Type 1 Diabetes Shows Promise
Novel reverse DNA vaccine improves pancreas function. Read More
SECA Presntation
Read More

[Please login to post comments]